Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Core Insights - Cellectis will report its financial results for Q4 and full year 2025 on March 19, 2026, after the US market closes [1] - An investor conference call and webcast will take place on March 20, 2026, at 8:00 AM ET, to discuss the financial results and business updates [2] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform [3] - The company employs an allogeneic approach for CAR T immunotherapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [3] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [3] Company Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [4] - The company is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [4]